Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: A review

Blood Cells, Molecules, and Diseases

Volumn 40, Issue 1, 2008, Pages 20-24

  Koh, Liang Piu ^a,b   Chao, Nelson J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

GVHD; Immune reconstitution; T cell depletion

Indexed keywords

ALEMTUZUMAB; ANTIGEN; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SIPLIZUMAB; T LYMPHOCYTE ANTIBODY; TACROLIMUS;

ADAPTIVE IMMUNITY; ARTICLE; CELLULAR IMMUNITY; DONOR; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; THERAPY EFFECT; WHOLE BODY RADIATION;

HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 36549019463     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2007.06.017     Document Type: Article

References (33)

1. Confer D.L. Unrelated marrow donor registries. Curr. Opin. Hematol. 4 (1997) 408-412
2. Beatty P.G., Mori M., and Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 60 (1995) 778-783
3. Hansen J.A., Petersdorf E., Martin P.J., and Anasetti C. Hematopoietic stem cell transplants from unrelated donors. Immunol. Rev. 157 (1997) 141-151
4. Howe C.W.S., and Radde-Stepaniak T. Hematopoietic cell donor registries. In: Thomas E.D., Blume K.G., and Forman S.J. (Eds). Hematopoietic Cell Transplantation. 2nd edition (1999), Blackwell Science, Malden, MA 503-512
5. Davies S.M., Kollman C., Anasetti C., et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 96 (2000) 4096-4102
6. McGlave P.B., Shu X.O., Wen W., et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 95 (2000) 2219-2225
7. Anasetti C. Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia. Leukemia 14 (2000) 502-504
8. Sierra J., Storer B., Hansen J.A., Martin P.J., et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant. 26 (2000) 397-404
9. Aversa F., Velardi A., Tabilio A., et al. Haploidentical stem cell transplantation in leukemia. Blood Rev. 15 (2001) 111-119
10. Rocha V., Wagner Jr. J.E., Sobocinkski K.A., et al. Graft-versus-host disease in children who have received a cord blood or bone marrow transplant from an HLA-identical sibling. N. Engl. J. Med. 342 (2000) 1846-1854
11. Laughlin M.J., Barker J., Bambach B., et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N. Engl. J. Med. 344 (2001) 1815-1822
12. Long G.D., Laughlin M., Madan B., et al. Unrelated umbilical cord blood transplantation in adult patients. Biol. Blood Marrow Transplant. 9 (2003) 772-780
13. Lang P., Bader P., Schumm M., et al. Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br. J. Haematol. 124 (2004) 72-79
14. Kawano Y., Takaue Y., Watanabe A., et al. Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor. Blood 92 (1998) 3123-3130
15. Peters C., Matthes-Martin S., Fritsch G., et al. Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment. Leukemia 13 (1999) 2070-2078
16. Passweg J.R., Kuhne T.M., Gregor M., et al. Increased stem cell dose, as obtained using currently available technology, may not be sufficient for engraftment of haploidentical stem cell transplants. Bone Marrow Transplant. 26 (2000) 1033-1036
17. Henslee-Downey P.J. Allogeneic transplantation across major HLA barriers. Best Pract. Res. Clin. Haematol. 14 (2001) 741-754
18. Rizzieri D.A., Koh L.P., Long G.D., et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J. Clin. Oncol. 25 (2007) 690-697
19. Barfield R.C., Otto M., Houston J., et al. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 6 (2004) 1-6
20. Hale G., Kimberly K., Lovins R., et al. CD3 depleted hematopoietic peripheral blood stem cell grafts in children with refractory hematologic malignancies undergoing transplantation from mismatched related donors. Blood 106 (2005) 451b [abstract]
21. Bethge W.A., Haegele M., Faul C., et al. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity. Exp. Hematol. 34 (2006) 1746-1752
22. Handgretinger R., Chen X., Pfeiffer M., et al. Feasibility and outcome of reduced intensity conditioning in haploidentical transplantation. Ann. N.Y. Acad. Sci. 1106 (2007) 279-289
23. Pelot M.R., Pearson D.A., Swenson K., et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol. Blood Marrow Transplant. 5 (1999) 133-143
24. Spitzer T.R., McAfee S.L., Dey B.R., et al. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 75 (2003) 1448-1751
25. Dey B.R., and Spitzer T.R. Current status of haploidentical stem cell transplantation. Br. J. Haematol. 135 (2006) 423-437
26. Spitzer T.R. Haploidentical stem cell transplantation: the always present but overlooked donor. Hematology Am. Soc. Hematol. Educ. Program (2005) 390-395
27. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol. Blood Marrow Transplant. 8 (2002) 377-386
28. Ogawa H., Ikegame K., and Yoshihara S. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol. Blood Marrow Transplant. 12 (2006) 1073-1084
29. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
30. Kanda Y., Oshima K., Asano-Mori Y., et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 79 (2005) 1351-1357
31. Amrolia P.J., Muccioli-Casadei G., Huls H., et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108 (2006) 1797-1808
32. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
33. van Rood J.J., Loberiza F.R., Zhang M.J., et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 96 (2002) 1572-1577